IgM antibody

100% Secure

Sheep anti Bovine IgM:Alk. Phos.

Sheep anti Bovine IgM:Biotin

Sheep anti Bovine IgM:FITC

Sheep anti Bovine IgM:HRP

Sheep anti Bovine IgM

Product Type
Polyclonal Antibody
Isotype
Polyclonal IgG
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
AAI19AB E WB 0.5 mg
AAI19B E WB 1 mg
AAI19F C F 1 mg
AAI19P E 1 mg
AAI19 E ID 1 mg
Sheep anti bovine IgM recognizes bovine IgM and shows no cross-reactivity with other bovine immunoglobulin classes in immunoelectrophoresis. Sheep anti bovine IgM may cross-react with IgM from other species.

Product Details

Target Species
Bovine
Product Form
Purified IgG conjugated to Alkaline Phosphatase - liquid
Product Form
Purified IgG conjugated to Biotin - liquid
Product Form
Purified IgG fraction conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG conjugated to Horseradish Peroxidase (HRP) - liquid
Product Form
Purified IgG - liquid
Antiserum Preparation
Antisera to bovine IgM were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG prepared by affinity chromatography.
Buffer Solution
50mM HEPES, 0.1M NaCl, 1mM MgCl2, 0.1mM ZnCl2
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
0.2%Bovine Serum Albumin
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
0.2% Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
0.2%Bovine Serum Albumin
Preservative Stabilisers
0.1% Proclin™ 300
0.2% Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
Immunogen
Purified bovine IgM.
Approx. Protein Concentrations
IgG concentration 0.5mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml

Storage Information

Storage
Store at +4oC.
DO NOT FREEZE..

This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch.
Shelf Life
12 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of despatch.
Shelf Life
18 months from date of despatch.

More Information

Acknowledgements
Proclin™ 300 is a trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow.
Regulatory
For research purposes only

Applications of IgM antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA 1/1000 1/10000
Western Blotting 1/5000 1/50000
ELISA 1:10000 1:100000
Western Blotting 1:10000 1:100000
Flow Cytometry 1/20 1/100
Immunohistology - Frozen 1/50 1/500
ELISA 1/10,000 1/100,000
ELISA 1/100 1/1000
Immunodiffusion
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Rabbit anti Sheep IgG (H/L):Biotin 5184-2304 1.5 ml C E F WB
Donkey anti Sheep/Goat IgG:DyLight®488 STAR88D488GA 0.1 mg F IF
Donkey anti Sheep/Goat IgG:DyLight®549 STAR88D549GA 0.1 mg F IF
Donkey anti Sheep/Goat IgG:DyLight®649 STAR88D649GA 0.1 mg F IF
Donkey anti Sheep/Goat IgG:FITC STAR88F 1 mg C
Donkey anti Sheep/Goat IgG:HRP STAR88P 1 ml C E P WB

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
AbGUARD® HRP Stabilizer Plus BUF052A 100 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052B 500 ml C E P WB
AbGUARD® HRP Stabilizer Plus BUF052C 1000 ml C E P WB
TMB Signal+ BUF054A 100 ml E
TMB Core BUF056A 100 ml E
TMB Core+ BUF062A 100 ml E

Application Based External Images

ELISA

Western Blotting

Product Specific References

References for IgM antibody

  1. Nebl, T. et al. (2002) Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes.
    J Biol Chem. 277 (45): 43399-409.
  2. Assad, A. et al. (2012) Immunophenotyping and characterization of BNP colostra revealed pathogenic alloantibodies of IgG1 subclass with specifity to platelets, granulocytes and monocytes of all maturation stages.
    Vet Immunol Immunopathol. 147: 25-34.
  3. Hamsten, C. et al. (2009) Recombinant surface proteomics as a tool to analyze humoral immune responses in bovines infected by Mycoplasma mycoides subsp. mycoides small colony type.
    Mol Cell Proteomics. 8: 2544-54.
  4. Mansilla FC et al. (2015) Safety and immunogenicity of a soluble native Neospora caninum tachyzoite-extract vaccine formulated with a soy lecithin/β-glucan adjuvant in pregnant cattle.
    Vet Immunol Immunopathol. 165 (1-2): 75-80.
  5. Hossain, M.M. et al. (2016) Multiplex Detection of IgG and IgM to Rift Valley Fever Virus Nucleoprotein, Nonstructural Proteins, and Glycoprotein in Ovine and Bovine.
    Vector Borne Zoonotic Dis. Jul 5. [Epub ahead of print]
  6. Van Meulder, F. et al. (2015) Analysis of the protective immune response following intramuscular vaccination of calves against the intestinal parasite Cooperia oncophora.
    Int J Parasitol. 45 (9-10): 637-46.
  7. Jankowska, A. et al. (2016) Humoral and cellular immune response to Histophilus somni recombinant heat shock protein 60 kDa in farm animals
    Veterinární Medicína. 60 (No. 11): 603-12.
  8. Trotta, M. et al. (2015) Simultaneous immunization of cattle with foot-and-mouth disease (FMD) and live anthrax vaccines do not interfere with FMD booster responses
    Trials in Vaccinology. 4: 38-42.